JME Ventures targets €40M for new longevity fund, JME Longevity I
What's the deal? Spain's JME VenturesDealroom has a profile for this one. Try Dealroom → is launching JME Longevity I, a venture capital fund that will back companies working to improve quality of life and life expectancy. It is targeting €30 million to €40 million, according to the market context, and law firm CuatrecasasDealroom has a profile for this one. Try Dealroom → advised on the fund's formation.
What's the endgame? The fund will focus on three areas: diagnosis and prevention, therapies, and platforms that develop better therapies. Its remit spans life sciences, health biotech, medical technology, digital health, pharmaceuticals, medical devices, and wellness.
Why now? JME Ventures has launched four venture funds to date, all centred on tech. Longevity marks a new direction that, in the firm's words, "requires a specific strategy and fund" (translated from Spanish).
Where's the money going? Investments are set to split roughly between the European Union (70%), the United States (20%), and Asia (10%). The mandate is broad and primarily European, running from prevention through to treatment and care.
The signal: The fund arrives amid growing investor interest in life sciences, though European capital clusters around biotech and companies near commercialisation rather than longevity specifically — Sofinnova recently closed a €725 million fund and Forbion announced €2.3 billion across two vehicles. Dedicated longevity capital remains thinner and more scattered, making JME's bet a differentiated sector play. The key test will be how much it finally raises and which companies it funds.
Read more: capital-riesgo.es
Image credit: Generated with Gemini